论文部分内容阅读
本临床研究采用多中心、随机、对照试验，评价泛昔洛韦治疗带状疱疹的疗效和安全性，以阿普洛韦作对照。泛昔洛韦治疗131例，阿昔洛韦治疗129例，共260例。研究结果为泛昔洛韦的止疱时间是2.82±1．76d,阿昔洛韦是4．01±2．8d;两组结痴时间分别是5．12±2．84d和6．06±2．74d；脱痴时间是1148±3．87d和13.29±3．65d；疼痛缓解时间是4．31±2.47d和6．6.71±4．33d；急性神经痛持续时间是9．15±3．94d和12．19±4．25d；疱疹后神经痛的发生，泛普洛韦是44／31（3．59％），阿昔洛韦是26／29（58．91％）。经统计学处理，两组间有显著性差异（P＜0.01）；泛昔洛韦在促进皮疹消退和缩短急性神经痛的时间方面比阿普洛韦更优越，且大大降低了后遗神经痛的发生率。两组药物不良反应的发生率分别是8．40％和6．98％（P＞0．05），两药对血液系统，肝、肾功能均无明显的影响。所有的临床资料证明，泛昔洛韦治疗带状疱疹疗效高，且耐受性好。
The clinical study of multi-center, randomized, controlled trials to evaluate the efficacy and safety of famciclovir in the treatment of shingles, with aplopride as a control. 131 cases were treated with famciclovir and 129 cases were treated with aciclovir, a total of 260 cases. The result of the study was that famciclovir had a blister time of 2.82 ± 1.76d and acyclovir was 4.01 ± 2.8d, and the time between the two groups was 5.12 ± 2.84d and 6.06 ± 2.74d ; The time of detoxification was 1148 ± 3.87d and 13.29 ± 3.65d; the pain relief time was 4.31 ± 2.47d and 6.6.71 ± 4.33d; the duration of acute neuralgia was 9.15 ± 3.94d and 12.19 ± 4.25 days. The incidence of postherpetic neuralgia was 44/31 (3.59%) with afoproc and 26/29 with acyclovir (58.91%). Statistically, there was a significant difference between the two groups (P <0.01); famciclovir was superior to aplopiride in accelerating rash subside and shortening the time of acute neuralgia, and greatly reduced the incidence of post-nociceptive neuralgia . Adverse reactions of the two groups were 8.40% and 6.98%, respectively (P> 0.05). The two drugs had no significant effect on the blood system, liver and kidney function. All the clinical data show that famciclovir treatment of shingles curative effect is high and well tolerated.